MARKETING ASSESSMENT OF DRUGS USED FOR TREATMENT OF ACID-RELATED DISEASES IN BISHKEK

Objective: Marketing assessment of anti-ulcer medicines in pharmacies in Bishkek. Methods: The study was used by data from the Department of Medicines and Medical Technology at the Ministry of Health of the Kyrgyz Republic on the registration of pharmaceutical products in the KR – State Registry of Medicines and Medical Products of 2019, as well as price sheets and invoices of wholesale pharmaceutical companies and retail pharmacies in Bishkek. Results: Depending on the value of the turnover rate (TR), the drugs were divided into three groups: drugs with slow TR (0.5 < К < 1.0); drugs with constant TR (0.26 < К < 0.49); drugs with high TR (0 < К < 0.25). According to the results of studies, proton pump inhibitors and colloidal bismuth-based drugs are high-end drugs of TR. Conclusions: We have determined that the pharmaceutical market in Bishkek demonstrates incomplete saturation of anti-ulcer drugs from the total number of registered medicines. At the same time, the largest part of the range are drugs from the group of proton pump inhibitors. Keywords: Anti-ulcer drugs, proton pump inhibitors, marketing assessment, turnover rate.

Download Full-text

An Analysis of the Transformation of Mega-Pharma’s Business Model toward the Emerging Market

Emerging Science Journal ◽

10.28991/esj-2020-01228 ◽

2020 ◽

Vol 4 (4) ◽

pp. 253-262

Author(s):

Yaeko Mitsumori

Keyword(s):

Patent Protection ◽

Business Models ◽

Emerging Market ◽

Patent Application ◽

Pharmaceutical Products ◽

Patent Law ◽

Pharmaceutical Market ◽

Pharmaceutical Companies ◽

Indian Market ◽

Application Data

The Trade-Related Aspects of Intellectual Property Rights（TRIPS) requires all member countries of the World Trade Organization (WTO) to introduce a TRIPS-compatible patent law into their countries. Due to the enforcement of TRIPS in 1995, India in 2005 revised its patent law and enacted the Patents (Amendment) Act, 2005. The 2005 ACT included product patent in pharmaceutical field. Due to the new patent law with product patent protection, large foreign capital pharmaceutical companies one after another re-entered the Indian market and started engaging in both R&D and production targeting the Indian market. However recent data shows the number of patent applications has been declining over the past several years and the number of patented drugs launched in India did not increase so rapidly. This study analyzes transitions of business models of foreign pharmaceutical companies in India based on the patent application data, and the trend of patented drugs in the market. A data analysis and a series of interviews with stakeholders were conducted. As a result of both a quantitative and a qualitative analysis, it was found that foreign pharmaceutical companies changed their strategies in the Indian pharmaceutical market. Since India was required to introduce product patents in the pharmaceutical area, there have been many arguments that once India introduces a product patent, the Indian pharmaceutical industry may decline due to the rapid introduction of foreign pharmaceutical products in the country; many academic papers were published in this context during that time. However, since 2005, when product patents were actually introduced in India, few academic papers were published. This study is unique as it discusses the effects of the introduction of product patents on the Indian pharmaceutical market.

Download Full-text

Comparative characteristics of proton pump inhibitor effectiveness in the treatment of gastric ulcer and duodenal ulcer

Current Issues in Pharmacy and Medical Sciences ◽

10.2478/cipms-2020-0011 ◽

2020 ◽

Vol 33 (2) ◽

pp. 57-60

Author(s):

Olesya P. Balitska ◽

Tamara A. Germanyuk ◽

Yuliia M. Hryhoruk ◽

Tatiana I. Ivko ◽

Yuliia O. Tomashevska ◽

...

Keyword(s):

Duodenal Ulcer ◽

Gastric Ulcer ◽

Proton Pump Inhibitor ◽

Proton Pump Inhibitors ◽

Proton Pump ◽

Inhibitory Effect ◽

Pharmaceutical Market ◽

Duodenal Ulcers ◽

Treatment Regimens

AbstractAim. The aim of this study is to evaluate the efficiency of proton pump inhibitors in the treatment of gastric and duodenal ulcers as based on literature.Materials and methods: The materials of this research are the results of 86 original studies on the effectiveness of proton pump inhibitors analysis.Methods. Descriptive, statistical, retrospective.Results and Conclusion. According to the clinical random researches, Omeprazole preparations are not included in the list due to proven better effectiveness of Esomeprazole drugs. Moreover, lansoprazole drugs are not included according to proven short-acid inhibitory effect. In addition, the brand of mentioned above preparation does not exist on the pharmaceutical market of Ukraine. Furthermore, rabeprazole preparations are presented in the research by Pariet (brand) and by the effective generic Barol, while pantoprazole preparations are represented in the research by Kontrolok (brand) and by the generic Pultset, as well as by Nolpaza. Herein, the Pantosan effect was not significantly different from the effect of Pultset and Nolpaza, but the preparation is much more expensive. In terms of efficiency (%), 4 week repair of mucosal defects was carried out by way of the following treatment regimens: Barol + Amoxicillin + Clarythromycin (90.9±6.2), Pariet + Amoxicillin + Clarythromycin (83±2.6), Kontrolok + Amoxicillin + Clarythromycin (100±1.3), Pultset + Amoxicillin + Clarythromycin (88±4.1), Nolpaza + Amoxicillin + Clarythromycin (72±4.1), Ezolonh + Amoxicillin + Clarythromycin (87.7±3.8), Neksium + Amoxicillin + Clarythromycin (96.1±3.1).

Download Full-text

Blockchain technology in the pharmaceutical supply chain: researching a business model based on Hyperledger Fabric

Information Technology and Nanotechnology ◽

10.18287/1613-0073-2019-2416-134-140 ◽

2019 ◽

pp. 134-140

Author(s):

S R Bryatov ◽

A A Borodinov

Keyword(s):

Supply Chain ◽

Control System ◽

Pharmaceutical Products ◽

Pharmaceutical Companies ◽

Counterfeit Drugs ◽

Development Environment ◽

Pharmaceutical Supply Chain ◽

Russian Market ◽

Medical Products ◽

Blockchain Technology

Pharmaceutical companies that manufacture, ship and supply products face difficulties in tracking their products, allowing counterfeiters to inject counterfeit drugs into the system. This situation is observed, in particular, in the Russian market of turnover of pharmaceutical products, although the problem has long been global. The ability of blockchain systems to pinpoint the origin of data makes them particularly suitable for pharmaceutical supply chain applications. The data stored in the blockchain distributed register on the identification of drugs produced by the plant, as well as records of their movements throughout the supply chain, can accurately determine the authenticity of pharmaceutical products lying on the shelves of pharmacies. The development and implementation of such a system can be a big step towards winning the exhausting fight against the easy availability of counterfeit drugs and medical products. In the first part of this work, the main characteristics and features of the functioning of blockchain systems will be studied. In the second and final part, the designed concept of the pharmaceutical turnover control system based on the blockchain technology Hyperledger Fabric using the Hyperledger Composer development environment will be investigated.

Download Full-text

QUALIMETRIC ANALYSIS OF PROTON PUMP INHIBITORS IN UKRAINE

Wiadomości Lekarskie ◽

10.36740/wlek201909212 ◽

2019 ◽

Vol 72 (9) ◽

pp. 1769-1773

Author(s):

Olha V. Makarenko ◽

Malika M. Karimova ◽

Alona M. Masheiko ◽

Nataliia M. Onul

Keyword(s):

Proton Pump Inhibitors ◽

Proton Pump ◽

Safety Profile ◽

Axiomatic Approach ◽

Dosage Forms ◽

Pharmaceutical Market ◽

Quality Indices ◽

Qualitative Properties ◽

Quality Properties ◽

The Subject

Introduction: On the pharmaceutical market of Ukraine, there are six international non-proprietary names of proton pump inhibitors (PPIs) – Omeprazole, Pantoprazole, Lansoprazole, Rabeprazole, Esomeprazole, Dexlansoprazole, which differ in a number of pharmacokinetic and pharmacodynamic parameters, safety profile, range of dosage forms and their cost. The aim: To investigate the competitiveness of proton pump inhibitors registered in Ukraine by comparing the parameters of their quality properties using the method of qualimetric analysis. Materials and methods: Qualimetric analysis is based on the deductive-axiomatic approach, which allows quantifying the qualitative properties of drugs and determining the degree of competitiveness of each of them in the pharmaceutical market of Ukraine. The qualitative properties of PPIs in terms of consumer are efficacy, safety, convenience of use and cost. The subject of the study was 133 trademarks of PPIs registered in Ukraine. Results: The highest qualimetric values were obtained by omeprazole (Kk = 0.73) and its S-isomer esomeprazole (Kk = 0.66). Pantoprazole was inferior to them to a certain extent (Kk = 0.64). Lansoprazole (Kk = 0.53), rabeprazole (Kk = 0.50) and dexlansoprazole (Kk = 0.44) had the lowest values of the quality indices. Conclusions: According to the results of the study of the PPIs’ competitiveness for parameters characterizing efficacy, safety, convenience of use and cost, assessed by qualimetric analysis, it has been established that the most completely and qualitatively satisfying consumer’s needs are omeprazole and its S-isomer, esomeprazole.

Download Full-text